Novartis AG vs Pfizer Inc.: Strategic Comparison
Key Differences at a Glance
| Field | Novartis AG | Pfizer Inc. |
|---|---|---|
| Revenue | $54.5B | $62.6B |
| Founded | 1996 | 1849 |
| Employees | 75,267 | 75,000 |
| Market Cap | $274.1B | $148.0B |
| Headquarters | Switzerland | United States |
Quick Stats Comparison
| Metric | Novartis AG | Pfizer Inc. |
|---|---|---|
| Revenue | $54.5B | $62.6B |
| Founded | 1996 | 1849 |
| Headquarters | Basel, Switzerland | New York, New York |
| Market Cap | $274.1B | $148.0B |
| Employees | 75,267 | 75,000 |
Novartis AG Revenue vs Pfizer Inc. Revenue — Year by Year
| Year | Novartis AG | Pfizer Inc. | Leader |
|---|---|---|---|
| 2025 | $54.5B | $62.6B | Pfizer Inc. |
| 2024 | $50.3B | $63.6B | Pfizer Inc. |
| 2023 | $45.4B | $59.6B | Pfizer Inc. |
| 2022 | N/A | $101.2B | Pfizer Inc. |
| 2021 | N/A | $81.3B | Pfizer Inc. |
Business Model Breakdown
Overview: Novartis AG vs Pfizer Inc.
This in-depth comparison examines Novartis AG and Pfizer Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Novartis AG on its own, evaluating Pfizer Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Novartis AG and Pfizer Inc. is widest.
On the headline numbers, Novartis AG reports annual revenue of $54.5B against $62.6B for Pfizer Inc., while their respective market capitalizations stand at $274.1B and $148.0B. Novartis AG is headquartered in Switzerland and Pfizer Inc. operates from United States, and those different home markets shape how each company competes.
Novartis AG: Novartis AG is a public company listed on NYSE under ticker NVS. Novartis makes money by discovering, developing, manufacturing, and commercializing patented medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology markets.
Pfizer Inc.: Pfizer has repeatedly reinvented itself around new therapeutic waves, from industrial fermentation and penicillin to Lipitor, vaccines, COVID products, and now oncology. The 2025 profile is not a pandemic windfall story; it is a large pharmaceutical company trying to rebuild a durable growth base.
Business Models: How Novartis AG and Pfizer Inc. Make Money
Novartis AG and Pfizer Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Novartis AG and Pfizer Inc..
Novartis AG business model: Novartis operates an elite, pure-play innovative medicines business model. After spinning off its Sandoz generic division, Novartis generates roughly $45 billion annually by discovering, patenting, and highly aggressively commercializing highly complex biopharmaceutical therapeutics and cutting-edge gene therapies, achieving pricing power and large operating margins.
Pfizer Inc. business model: Pfizer operates a prominent, volume-driven biopharmaceutical model. It relies entirely on large scale. The company does not simply rely on slow internal R&D; it operates as a substantial M&A engine, aggressively acquiring smaller biotech firms that have promising drugs, and then using its unparalleled global manufacturing and sales force to maximize the commercial revenue before the patents expire.
Competitive Advantage: Novartis AG vs Pfizer Inc.
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Novartis AG stack up against those of Pfizer Inc..
Novartis AG competitive advantage: Novartis's advantage is a focused patented-medicine portfolio, global commercial reach, scale in clinical development, and specialty platforms such as radioligand therapy.
Pfizer Inc. competitive advantage: Pfizer advantage is scale: global regulatory expertise, manufacturing capacity, clinical development experience, commercial infrastructure, vaccine capabilities, and the ability to acquire or partner for scientific platforms.
Growth Strategy: Where Novartis AG and Pfizer Inc. Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Novartis AG and Pfizer Inc. each plan to expand from here.
Novartis AG growth strategy: Novartis AG's growth strategy centers on this advantage: Novartis's advantage is a focused patented-medicine portfolio, global commercial reach, scale in clinical development, and specialty platforms such as radioligand therapy.
Pfizer Inc. growth strategy: Pfizer growth strategy emphasizes oncology, vaccines, internal medicine, obesity and metabolic research, business development discipline, cost reduction, and global commercial execution. Chris Boshoff became Chief Scientific Officer and President, Research & Development effective January 1, 2025.
Financial Picture: Novartis AG vs Pfizer Inc.
A closer look at the financial trajectory of Novartis AG and Pfizer Inc. rounds out the comparison.
Novartis AG: Novartis AG reported FY2025 revenue of $54.532B and net income of $13.967B.
Pfizer Inc.: Pfizer reported $62.579 billion of FY2025 revenue, compared with $63.627 billion in FY2024 and $59.553 billion in FY2023. Net income was $7.771 billion in FY2025. Pfizer employed approximately 75,000 people worldwide as of December 31, 2025.
Company-Specific SWOT Notes
Novartis AG
After Sandoz and Alcon separations, Novartis is concentrated around branded, higher-margin medicines and specialty platforms.
Large franchises can lose sales quickly when exclusivity ends or payers switch patients to generics and biosimilars.
Radioligand therapy, oncology, immunology, and cardiovascular launches can offset mature-product pressure.
Drug-price controls, reimbursement restrictions, safety findings, and clinical failures can materially affect growth.
Pfizer Inc.
Pfizer has manufacturing, regulatory, clinical, and commercial infrastructure that few competitors can match globally.
Major products face loss of exclusivity and pricing pressure, requiring strong replacement revenue.
The Seagen acquisition gives Pfizer a larger oncology platform and ADC pipeline if clinical and commercial execution succeeds.
Medicare negotiation, generic competition, and failed pipeline readouts can compress revenue and margins.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | Pfizer Inc. | Pfizer Inc. reports the larger revenue base ($62.6B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | Pfizer Inc. | Founded in 1996 vs 1849. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | Tied | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | Novartis AG | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | Novartis AG | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
Pfizer Inc. reports the larger revenue base ($62.6B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1996 vs 1849. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Novartis AG or Pfizer Inc.?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Novartis AG vs Pfizer Inc.
Is Novartis AG better than Pfizer Inc.?
Verdict: Between Novartis AG and Pfizer Inc., Pfizer Inc. is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, Pfizer Inc. comes out ahead in this Novartis AG vs Pfizer Inc. comparison.
Who earns more — Novartis AG or Pfizer Inc.?
Pfizer Inc. earns more with $62.6B in annual revenue versus Novartis AG's $54.5B. Pfizer Inc. leads on total revenue based on latest verified figures.
Which company has higher revenue — Novartis AG or Pfizer Inc.?
Novartis AG reported $54.5B, while Pfizer Inc. reported $62.6B. The revenue leader is Pfizer Inc. based on latest verified figures.
Novartis AG revenue vs Pfizer Inc. revenue — which is higher?
Novartis AG revenue: $54.5B. Pfizer Inc. revenue: $54.5B. Pfizer Inc. has the larger revenue base of the two companies.
Sources & References
- Novartis AG Corporate Website
- Novartis AG Annual Report 2025 - Revenue and Financial Data
- sec.gov
- novartis.com
- SEC EDGAR: Pfizer Inc. Annual Filings (10-K, 8-K)
- Pfizer Inc. Corporate Website
- Pfizer Inc. Annual Report 2025 - Revenue and Financial Data
- sec.gov
- investors.pfizer.com
- pfizer.com
- investors.pfizer.com